Item 5. Market for Registrant’s Common Equity
Item 5. Market for Registrant’s Common
Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Market Information
Our common stock is traded
on NYSE American under the symbol “OSTX.”
Holders
As of March 28 2025, there
were 142 holders of record of our common stock. The actual number of holders is greater than this number of record holders and includes
stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.
Dividends
We have never paid a cash
dividend on our common stock and do not expect to pay a cash dividend in the near future. We currently intend to retain future earnings,
if any, to finance our operations and expand our business.
Securities Authorized for Issuance Under Equity Compensation Plans
The following table sets forth
information as of December 31, 2024 with respect to our common stock that may be issued under our incentive compensation plans and other
option grants.
Plan Category
Number of
Securities
to be
Issued Upon
Exercise of
Outstanding
Options,
Warrants and
Rights
(a)
Weighted-
Average
Exercise
Price of
Outstanding
Options,
Warrants and
Rights
(b)
Number of
Securities
Remaining
Available for
Future Issuance
Under Equity
Compensation
Plans
(Excluding
Securities
Reflected in
Column (a))
Equity Compensation Plans Approved by Security Holders
—
$ —
—
Equity Compensation Plans Not Approved by Security Holders
2,870,000
1.86
1,130,000
Total
2,870,000
$ 1.86
1,130,000
Sales of Unregistered Securities
During the quarter ended December
31, 2024, we issued 25,000 shares of our common stock in exchange for marketing services. Additionally, we issued 6,506 shares of our
common stock to a former convertible noteholder to settle an outstanding interest obligation following the conversion of our outstanding
convertible notes upon consummation of our initial public offering.
57
Use of Proceeds
On July 31, 2024, our registration
statement on Form S-1 (File No. 333-276350) was declared effective by the SEC for our initial public offering, which was underwritten
by Brookline Capital Markets. At the closing of our initial public offering on August 2, 2024, we sold 1,600,000 shares of common stock
at an initial public offering price of $4.00 per share and received gross proceeds of $6.4 million, which resulted in net proceeds to
us of approximately $6.0 million, after deducting underwriting discounts and commissions of approximately $0.4 million. As of March 28,
2025, we estimate that we have used approximately $6 million of the proceeds from our initial public offering for general corporate purposes,
including to advance the development of OST-HER2 and OST-tADC. There has been no material change in the planned use of proceeds from that
described in the final prospectus for our initial public offering filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act.
Issuer Purchases of Equity Securities
During the year ended December
31, 2024, we did not repurchase any equity securities.
Item 6. Reserved.